Biopharma company GSK (LSE: GSK) (NYSE: GSK) announced on Monday that it has secured Fast Track designation from the US FDA for bepirovirsen, an investigational antisense oligonucleotide (ASO) targeting chronic hepatitis B (CHB).
The designation expedites drug development for serious conditions with unmet medical needs. Bepirovirsen's potential was supported by phase IIb trials B-Clear and B-Sure, with ongoing phase III program B-Well.
CHB affects nearly 300 million people globally, with current treatments offering a less than 2-8% functional cure rate.
Bepirovirsen is in phase III development, showing promise for a clinically meaningful functional cure response when combined with oral nucleoside/nucleotide analogues.
Correction - DeepHealth expands FDA clearance for SmartMammo Dx with GE HealthCare integration
DeepHealth expands FDA clearance for SmartMammo Dx with GE HealthCare integration
Formosa Pharmaceuticals licenses eye drops for Switzerland and Liechtenstein
Galderma reports Phase III data for nemolizumab in prurigo nodularis published in JAMA Dermatology
AOP Health's Rapiblyk approved by FDA for atrial fibrillation and atrial flutter
PTC Therapeutics to sell Priority Review Voucher for USD150m
Novartis' Kisqali approved in EU for broader population of high-risk early breast cancer patients
Merck reports positive Phase 3 ZENITH results for WINREVAIR in PAH treatment
Alnylam's sNDA for vutrisiran accepted by FDA; PDUFA date set for March 2025
GSK plc announces US FDA acceptance of review for Blenrep combinations in multiple myeloma
Hanmi Pharmaceutical and Beijing Hanmi Pharmaceutical announce progress in BH3120 clinical trial
Johnson & Johnson seeks FDA approval for subcutaneous TREMFYA